Umer Raffat
Stock Analyst at Evercore ISI Group
(1.42)
# 3,546
Out of 5,015 analysts
21
Total ratings
55.56%
Success rate
-4.17%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Initiates: Outperform | n/a | $52.87 | - | 1 | Feb 25, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $19.14 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $14.26 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $1.34 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $26.79 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $31.21 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $22.31 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Outperform | n/a | $20.03 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $11.82 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $42.16 | - | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $31.70 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.60 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.87 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $960 | $31.23 | +2,973.97% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $290.13 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $7.21 | +565.74% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $135.43 | - | 1 | Feb 23, 2017 |
Metsera
Feb 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $52.87
Upside: -
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $19.14
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $14.26
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.34
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $26.79
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $31.21
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $22.31
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $20.03
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $11.82
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $42.16
Upside: -
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $31.70
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.60
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.87
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $960
Current: $31.23
Upside: +2,973.97%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $290.13
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $7.21
Upside: +565.74%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $135.43
Upside: -